Premium
Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance
Author(s) -
Xu ZuoFeng,
Xie XiaoYan,
Kuang Ming,
Liu GuangJian,
Chen LiDa,
Zheng YanLing,
Lu MingDe
Publication year - 2014
Publication title -
journal of clinical ultrasound
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.272
H-Index - 61
eISSN - 1097-0096
pISSN - 0091-2751
DOI - 10.1002/jcu.22141
Subject(s) - medicine , radiofrequency ablation , hepatocellular carcinoma , ablation , percutaneous , radiology , ultrasound , liver tumor , liver cancer , nuclear medicine
Background To evaluate the feasibility, accuracy, and utility of sonography (US) and CT fusion imaging guidance for radiofrequency ablation (RFA) of malignant liver tumors not visualized on conventional US. Methods Seventy‐seven patients with hepatocellular carcinoma and 15 patients with metastatic liver cancer with a total of 136 lesions underwent RFA with US and CT fusion imaging guidance. The mean number of punctures, success rate of a single ablation session, local tumor progression rates, and long‐term outcome were evaluated. Treatment efficacy was evaluated by dynamic CT and contrast‐enhanced US 1 month after RFA. Results RFA was technically feasible in all patients, and no major complications occurred. The mean ± SD time needed to synchronize US and CT images was 13.9 ± 11.9 minutes (range, 5–55 minutes). The success rate of a single ablation session was 83.8% (114/136), and tumor residue was present in 7.4% of lesions (10/136). The mean number of treatment sessions was 1.2 ± 0.5 sessions. During follow‐up, local tumor progression was observed for 15 (11.9%) lesions. Distant tumor recurrence was found in 51 (55.4%) patients. Conclusions US and CT fusion‐assisted RFA is a safe and efficacious treatment for patients with hepatocellular carcinoma and metastatic liver cancer. © 2014 Wiley Periodicals, Inc. J Clin Ultrasound 42 :321–330, 2014